Drug & intervention

doxycycline

RxCUI 3640

Clinical trials12
Recruiting0
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Doxycycline

Doxycycline, sold under the brand names Vibramycin and Doryx, among others, is a broad-spectrum antibiotic of the tetracycline class used in the treatment of infections caused by bacteria and certain parasites. It is used to treat bacterial pneumonia, acne, chlamydia infections, Lyme disease, cholera, typhus, and syphilis, and is sometimes used to prevent malaria. Doxycycline may be taken by mouth or intravenously. Common side effects include diarrhea, nausea, vomiting, abdominal pain, and an increased risk of sunburn. Use during pregnancy is not recommended. Doxycycline can be used in children of all ages, including for Lyme disease and rickettsial infections. Like other agents of the tetracycline class, it slows or kills bacteria by inhibiting protein production. It kills Plasmodium—microorganisms associated with malaria—by targeting a plastid organelle, the apicoplast. Doxycycline post-exposure prophylaxis (doxyPEP) is also used to prevent sexually transmitted infections, particularly when skin or fluid contact has occurred, such as if protection was not used in men who have sex with men, and is supported by CDC guidelines. Doxycycline was patented in 1957 and came into commercial use in 1967. It is on the World Health Organization's List of Essential Medicines. Doxycycline is available as a generic medicine. In 2023, it was the 77th most commonly prescribed medication in the United States, with more than 8 million prescriptions.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

12 shown
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibNCT06120140 · 2024-02-16
ACTIVE_NOT_RECRUITING
Effect of Doxycycline in Levodopa Treated Parkinson's Disease PatientsNCT05492019 · 2022-07-01
UNKNOWN
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NTNCT03435952 · 2018-07-10
ACTIVE_NOT_RECRUITING
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine CancerNCT02874430 · 2016-06-08
TERMINATED
Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot UlcersNCT02036528 · 2014-01-01
TERMINATED
Combining Doxycycline With Bone-Targeted Therapy in Patients With Metastatic Breast CancerNCT01847976 · 2013-08-01
COMPLETED
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRONCT01465802 · 2011-12-26
COMPLETED
Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity UlcersNCT00764361 · 2009-01-01
COMPLETED
Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced RashNCT00803842 · 2008-10-01
WITHDRAWN
A Pilot Study of Inflammatory Markers in Alzheimer's DiseaseNCT00715858 · 2008-05-01
UNKNOWN
Relationship of Periodontal Disease Treatment and Type 2 Diabetes Mellitus in the Gullah PopulationNCT01798225 · 2007-12-01
COMPLETED
Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal FluidNCT00439166 · 2007-02-01
COMPLETED

Conditions being studied

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.